Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Arg-BPC-157 5mg
Arg-BPC-157 5mg

Arg-BPC-157 5mg

ARG BPC-157 5 mg — arginine salt of regenerative pentadecapeptide (Body Protection Compound) in a vial with lyophilisate for laboratory tests, Endogenic line. Arginine can increase stability and solubility. RUO reagent

26,99 €
With code BLACK: 21,59 € Lowest price in the 30 days before the discount: 26,99 €
Buy more, pay less
Fast shipping
Free delivery from 350 €
Returns policy
View the laboratory analysis report Peptide Calculator

ARG BPC-157 5 mg - arginine salt of regenerative pentadecapeptide, research reagent

  • ARG-BPC-157: the arginine salt of BPC-157.
  • 5 mg lyophilisate in a vial.
  • Research Use Only reagent, not a medicinal product.

Product status information

Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.

Regulatory framework – WADA S0 status

BPC-157 is located from 2022 on the WADA prohibited list – category S0 (unapproved substances). The S0 category includes pharmacological compounds that have not been approved by any regulatory agency for use in humans (no registration as a drug) and yet are used in the context of supportive care. BPC-157 — regardless of salt form — never completed the full registration path: Phase II clinical development (PL 14736, Diagen) was abandoned in 2014.

In the Pro-Body catalog, ARG BPC-157 appears only as RUO research reagent, not as an adjunct. Registered athletes (ADAMS) must check the current list of prohibited substances before making any decision.

ARG BPC-157 is a known gastric pentadecapeptide in a different salt form, not a new molecule. The peptide sequence remains the same as in the classic BPC-157 (GEPPPGKPADDAGLV), the counterion changes: instead of the most common acetate, the molecule appears here as arginine salt. This distinction, which is easy to miss in a trade name, has real consequences for laboratory work – it affects the mass of the salt, the stability and solubility of the reagent, although it does not change what amino acid chain the researcher has in the vial.

BPC-157 itself remains one of the most widely reported peptides for regeneration in the preclinical literature on connective tissue repair. Predrag Sikiric’s team isolated it in Zagreb in 1991 as a fragment of a larger protective protein of the gastric mucosa (Body Protection Compound). Thirty years later, the molecule is still not registered as a drug in any jurisdiction, and its clinical development is stuck in Phase II.

Nevertheless, the literature describes six axes of its molecular activity – with the best documented modulation of the VEGF/VEGFR2 pathway (angiogenesis) and the FAK-paxillin cascade (fibroblast migration) in tendon repair models. This reagent is supplied as lyophilisate in a vial with a nominal content of 5 mg ARG BPC-157, in line Endogenic. The lyophilized format requires reconstitution with bacteriostatic water before experimental work – unlike ready-made factory solutions in applicators. This is a classic form of peptide reagent for researchers who set the starting concentration for a specific model.

General description

ARG BPC-157 (arginine salt BPC-157) is stable gastric pentadecapeptide with a sequence of fifteen amino acids, supplied in the form of a salt with arginine as a counterion. BPC-157 itself is not de novo engineered – it is a fragment of a naturally occurring protective protein of human gastric juice. This feature explains one of its most frequently reported properties: exceptional proteolytic stability, i.e. resistance to digestion in the gastrointestinal environment, where most peptides are rapidly degraded.

The arginine salt form is a variant that appears in the peptide reagents market next to the dominant acetate. Arginine as a counterion can increase the stability and solubility of the peptide compared to the free form – this is a physicochemical difference, not a difference in the mechanism of action of the peptide. The amino acid chain remains identical, so the molecular profile described in the literature applies to both salt variants the same.

In the preclinical literature, BPC-157 is described primarily in context connective tissue reparation — models of Achilles tendon rupture and cutting, ligament and muscle damage — and protection of the digestive tract (models of stomach ulcers, colitis). This makes it a common reference point in research on peptides for injuries soft tissues. Secondary research directions include the central nervous system axis (models of anxiety and depression) and angiogenesis, i.e. the creation of new blood vessels.

In the Pro-Body catalog the ARG BPC-157 belongs to Pillar I – regenerative peptides. The 5 mg lyophilisate vial format makes it a reagent for precisely controlled experimental series in which the researcher himself sets the starting concentration by reconstitution with bacteriostatic water. The single-component line remains the reference point for research on BPC-157 itself – separately from regenerative blends in which the arginine salt of BPC-157 is combined with a fragment of Thymosin Beta-4.

What is ARG BPC-157 - Sequence, Class and Salt Form

ARG BPC-157 is arginine salt of synthetic pentadecapeptide corresponding to a 15 amino acid fragment of the human gastric protective protein. The peptide sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (single letter notation: GEPPPGKPADDAGLV). The molecular formula of the free peptide is C₆₂H₉₈N₁₆O₂₂, molar mass of free peptide 1419.53 g/mol, number CAS 137525-51-0 (the number refers to the peptide, regardless of the salt form).

In the form of arginine salt, the mass of salt is higher by the contribution of arginine as a counterion — the value measured by mass spectrometry for the salt differs from the mass of the free peptide and is subject to verification in the batch COA. The three proline residues in positions 3–5 (PPP motif) have a structural function – they stiffen the chain and impede access by proteolytic enzymes.

This is a molecular explanation for the peptide stability observed in the literature in the gastrointestinal environment, where free peptides degrade within minutes. Unlike acylated peptides (like semaglutide), BPC-157 does not have an attached fatty acid chain – its stability results from the sequence itself, not from post-translational modification. The form of the salt (arginine vs. acetate) affects the behavior of the reagent in storage and solution, not the sequence itself or the proline motif.

He isolated the molecule Predrag Sikiric’s team in Zagreb in 1991. Clinical development was conducted by Diagen under the designation PL 14736; Phase II was abandoned in 2014 and the peptide was never registered as a drug. Since then, BPC-157 – in both salt variants – has functioned solely as a research reagent.

Chemical characteristics

Parameter Value
Name ARG BPC-157 (BPC-157 arginine salt), BPC-157 arginate
Class Gastric pentadecapeptide (a fragment of a protective protein), a form of arginine salt
Sequence (1 letter) GEPPPGKPADDAGLV
Sequence (3-letter) Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Number of amino acids 15
Molecular formula (free peptide) C₆₂H₉₈N₁₆O₂₂
Molar mass (free peptide) 1419.53 g/mol
Mass of salt higher by the contribution of arginine as a counterion (verification in the COA of the batch)
CAS number (peptide) 137525-51-0
Salt variant Arginine salt (vs acetate); arginine may increase stability/solubility
Origin Fragment of the protective protein of gastric juice (isolation: Zagreb, 1991)
Physical form Lyophilisate in a vial (requires reconstitution)
Nominal content 5 mg ARG BPC-157/vial
Product line Endogenous
HPLC purity ≥98%
Identity confirmation Q-TOF mass spectrometry (sequence + salt mass)

Mechanism of action at the molecular level

In the preclinical literature, BPC-157 is described as a multidirectional compound – the literature indicates six complementary axes of molecular activity. The mechanism applies to the peptide itself, so it applies to the arginine salt as well as to the acetate. Below, each axle with the name of the route and the practical gear ratio observed in the research models.

VEGF/VEGFR2 modulation – angiogenesis

The best documented axis. VEGF (vascular endothelial growth factor) and its receptor VEGFR2 are the central pathway of angiogenesis – the formation of new blood vessels. In rat Achilles tendon rupture models (Chang et al. 2011), BPC-157 increased VEGFR2 expression in tendon cells and increased neovascularization in the area of ​​injury. In experimental practice: better vascularization of the regenerating connective tissue was observed as a factor of faster reparation in an animal model. Angiogenesis is a bottleneck here – the tendon is a poorly vascularized tissue, and without a blood supply, repair progresses slowly.

FAK-paxillin pathway – fibroblast migration

FAK (focal adhesion kinase) and paxillin regulate cell adhesion and migration. Chang et al. (2011) showed that BPC-157 activates the FAK-paxillin cascade in tendon fibroblasts, increasing their migration towards the wound. In practice: fibroblasts are “repair” cells of connective tissue – they produce collagen and rebuild the matrix. Faster migration means faster settlement of the damaged area.

NO/eNOS axis – microcirculation

BPC-157 has been associated in the literature with modulation of the nitric oxide (NO) pathway via endothelial NO synthase (eNOS). Nitric oxide dilates blood vessels and improves microcirculation in the area of ​​damaged tissue. This is a complementary axis to VEGF: VEGF builds new vessels, NO regulates the flow in existing ones.

Serotonergic and dopaminergic modulation

In behavioral models, BPC-157 showed activity on the central nervous system axis – effects on the serotonergic and dopaminergic systems as well as anti-anxiety and anti-depressant effects were reported in rodent models. This is a secondary, but recurring, direction of research on the molecule in the literature. The mechanism remains the subject of further work.

Anti-inflammatory effect – NF-κB, TNF-α, IL-6

In rat models of colitis, Tkalcević et al. (2007) reported a reduction in the severity of inflammatory lesions and a decrease in pro-inflammatory markers. The literature associates this effect with the modulation of the NF-κB pathway and the reduction of pro-inflammatory cytokines TNF-α and IL-6. In practice: limiting the inflammatory reaction in the area of ​​​​damage, which promotes tissue remodeling.

Proteolytic stability

The sixth axis concerns the molecule itself: BPC-157 shows resistance to digestion in the gastrointestinal environment. The three-proline motif stiffens the chain and limits the access of proteases. From a researcher’s perspective, this feature simplifies the work – the peptide maintains its integrity under conditions where most peptides are degraded. The form of the arginine salt may additionally influence storage stability and solubility, although the proteolytic stability itself results from the sequence.

Reference data mainly comes from the work of Sikiric’s team (e.g. Sikiric et al. 1993, 2011) and groups working on tendon repair (Chang et al. 2011; Krivic et al. 2006) and gastrointestinal tract (Tkalcević et al. 2007).

IMPORTANT DISTINCTION – Arginine Salt vs. BPC-157 Acetate

ARG BPC-157 and BPC-157 acetate are the same peptide sequence (GEPPPGKPADDAGLV) – only the salt counterion (counterion) differs from them. In ARG BPC-157, the counterion is arginine; in BPC-157 acetate (BPC-157 acetate) — acetate. There are two consequences of the distinction. First of all – mass. The mass measured by mass spectrometry for the salt differs from the mass of the free peptide by the contribution of the counterion, so the mass of the arginine salt differs from the mass of the acetate salt. The type of salt must be taken into account when interpreting the MS spectrum and when making molar conversions.

Secondly – physicochemical properties. Stability, solubility and hygroscopicity depend on the type of salt; arginine as a counterion can increase stability and solubility. Salt doesn’t change that What does the peptide (the mechanism relates to the sequence), but affects How behaves in storage and in solution. Identity decides sequence + mass MS in COA: the sequence GEPPPGKPADDAGLV confirms that it is BPC-157, and the measured salt mass allows us to verify the type of counterion. COA reading instructions – see section below.

Applications in scientific research

ARG BPC-157 as an RUO reagent is used in several research directions. The 5 mg lyophilized vial format works well in precisely controlled experimental series – the researcher sets the initial concentration by reconstitution, selecting the volume of solvent for a specific model.

Tendon, ligament and muscle repair. Models of rupture and cutting of the Achilles tendon, patellar ligament injuries, and skeletal muscle injuries. Endpoints: mechanical breaking strength, histology (collagen density, fiber organization), angiogenesis markers (VEGF, VEGFR2, CD31), migration markers (FAK, paxillin). BPC-157 functions as a reference pro-angiogenic compound in comparative work on connective tissue reparation.

Gastrointestinal tract – models of ulcers and colitis. Gastric ulcer models induced by ethanol or NSAIDs, models of colitis (acetic acid, TNBS). Endpoints: ulcer surface, inflammatory index, pro-inflammatory markers (TNF-α, IL-6, NF-κB), mucosal integrity. This is historically the first area of ​​research on the molecule consistent with its gastric origin. In intestinal models, BPC-157 is sometimes combined with an anti-inflammatory tripeptide – an example is KPV peptide in oral enteric blends.

Central nervous system – models of anxiety and depression. Rodent behavioral models (forced swimming test, elevated plus maze), analyzes of the serotonergic and dopaminergic systems, stress markers on the hypothalamic-pituitary-adrenal axis. A secondary but repeatable direction of research on peptide neuroactivity.

Angiogenesis and wound healing. Skin wound healing models, endothelial cell cultures, tube formation assays. Semiquantitative assessment of the VEGF/VEGFR2 and NO/eNOS pathway. BPC-157 as a tool for studying the mechanisms of neovascularization.

The influence of salt form on physicochemical properties. Comparison of the stability, solubility and hygroscopicity of BPC-157 arginine salt and BPC-157 acetate under storage conditions and in solution – a direction specific to the arginine variant, important when selecting the form of the reagent for a specific protocol.

Summary

ARG BPC-157 is arginine salt stable gastric pentadecapeptide (GEPPPGKPADDAGLV, free peptide mass 1419.53 g/mol) isolated in Zagreb in 1991 as a fragment of the protective protein of gastric juice. The form of arginine salt differs from the dominant acetate only in the counterion – the same sequence, different salt mass, partly different physicochemical properties (arginine can increase stability and solubility).

Six axes of molecular activity of the peptide have been described in the preclinical literature – with the best documented modulation of the VEGF/VEGFR2 pathway (angiogenesis) and the FAK-paxillin cascade (fibroblast migration) in tendon repair models. The 5 mg lyophilized vial format (Endogenic line) provides researchers with material for precisely controlled series in which the starting concentration is established by reconstitution with bacteriostatic water.

The regulatory profile remains clear: BPC-157 is not registered as a drug (phase II abandoned in 2014), and as of 2022 it is on the WADA list in category S0 – regardless of salt form. In the Pro-Body ARG catalog, BPC-157 appears as a Research Use Only reagent – a molecular tool for laboratory research, with HPLC purity ≥98%, MS Q-TOF confirmation (sequence + salt mass) and COA for each batch.

The broader context of peptide regeneration and comparison protocols of BPC-157 with Thymosin Beta-4 fragment is discussed in the review BPC-157 and TB-500 for regeneration; a separate form of the same peptide in the oral version is described in the entry o BPC-157 capsules.

Bibliography

  1. Sikirić P, Petek M, Rucman R, Seiwerth S, Grabarević Z, et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. PubMed
  2. Chang C. H., Tsai W. C., Lin M. S., Hsu Y. H., Pang J. H. S. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. PubMed
  3. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. PubMed
  4. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. PubMed
  5. Tkalcević VI, Cuzic S, Brajsa K, Mildner B, Bokulic A, et al. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. PubMed

BPC-157 it is not registered as a medicine in the EU or the USA (clinical development of PL 14736 stopped at phase II in 2014) and since 2022, it has been on the WADA prohibited list in category S0 (unapproved substances) — regardless of the form of salt. Registered Athletes (ADAMS) must check the current list before making any decision. The information in the description is educational and scientific in nature and refers to results reported in preclinical literature – it does not constitute medical advice or administration instructions.